Cargando…

Tumor Immunotargeting Using Innovative Radionuclides

This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kraeber-Bodéré, Françoise, Rousseau, Caroline, Bodet-Milin, Caroline, Mathieu, Cédric, Guérard, François, Frampas, Eric, Carlier, Thomas, Chouin, Nicolas, Haddad, Ferid, Chatal, Jean-François, Faivre-Chauvet, Alain, Chérel, Michel, Barbet, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346935/ https://www.ncbi.nlm.nih.gov/pubmed/25679452 http://dx.doi.org/10.3390/ijms16023932

Ejemplares similares

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Sensitivity of pretargeted immunoPET using (68)Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with (18)FDG PET-CT
por: Foubert, Fanny, et al.
Publicado: (2018)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
por: Bodet-Milin, Caroline, et al.
Publicado: (2019)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

ImmunoPET to help stratify patients for targeted therapies and to improve drug development
por: Kraeber-Bodere, Françoise, et al.
Publicado: (2016)

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
por: Carlier, Thomas, et al.
Publicado: (2013)

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
por: Eychenne, Romain, et al.
Publicado: (2021)

Cell Tracking in Cancer Immunotherapy
por: Perrin, Justine, et al.
Publicado: (2020)

From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450
por: Carlier, Thomas, et al.
Publicado: (2020)

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
por: Gouard, Sébastien, et al.
Publicado: (2020)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy
por: Bailly, Clément, et al.
Publicado: (2014)

Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials
por: Bailly, Clément, et al.
Publicado: (2016)

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
por: Bailly, Clément, et al.
Publicado: (2019)

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
por: Rousseau, Caroline, et al.
Publicado: (2011)

Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
por: Pallardy, Amandine, et al.
Publicado: (2020)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

[(18)F]-Fludarabine for Hematological Malignancies
por: Barré, Louisa, et al.
Publicado: (2019)

Innovative radiopharmaceuticals in oncology and neurology
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2017)

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
por: Bodet-Milin, Caroline, et al.
Publicado: (2015)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma
por: Bailly, Clement, et al.
Publicado: (2017)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
por: Bailly, Clément, et al.
Publicado: (2019)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

Interest of Pet Imaging in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2019)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer
por: Mathieu, Cédric, et al.
Publicado: (2015)

Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2014)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
por: Bodet-Milin, Caroline, et al.
Publicado: (2023)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
por: Barbet, Jacques, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p2r0pgps169r0iq3dcncmi6193